1. (S/NOFORN-CL) GENERAL

1.1 The objective of this effort is to investigate a particular aspect of the psychoenergetic phenomena known as remote viewing that has potential military intelligence application. Coordinate Remote Viewing (CRV) is a staged technique which utilizes coordinates to facilitate acquisition of a remote viewing target.

1.2 Major goals are the determination if CRV technology can be successfully transferred to INSCOM personnel with a corresponding increase in the reliability of a remote viewer.

2. (S/NOFORN-CL) SPECIFIC TASK

2.1 Train army personnel in CRV Stages III and IV.

2.1.1 Initiate training at the highest skill level (CRV Stage) of the trainee.

2.1.2 Training for each CRV stage will normally be divided into three two week working sessions. The Session dates will be mutually agreed to by SRI and INSCOM.

2.1.3 After successful completion of CRV Stage III, schedule the trainee to begin CRV Stage IV.

2.2 Determine the potential of the trainee for further training.

3. (U) SECURITY

Military security requirements in the performance of this contract shall be maintained in accordance with DD Form 254 attached hereto. The highest classification involved in the performance of this contract is SECRET-NO FOREIGN DISSEMINATION.

4. (S/NOFORN-CL) DELIVERABLES: The contractor will provide the following.

4.1 State-of-The-Art CRV training.

4.2 Progress report (2 copies): Written evaluation of trainee progress at the completion of each two week working session.

4.3 Final Report:

4.3.1 A final report in 3 copies will be furnished within 30 days after completion of the CRV stage.

4.3.2 Report will include a summary of the training presented; an evaluation of the trainee's ability to understand the training; and a summary of the trainee's accomplishments during the training period.

4.3.3 Report should also include an evaluation of the trainee's future remote viewing capabilities, and a recommendation concerning further training.

Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110001-4

5. (S/NOFORN-CL) POST TRAINING ACCESS: After the completion of each CRV training stage personnel involved in the training program will have reasonable access to INSCOM personnel trained to assist in further evaluation of CRV.

6. (U) SPECIAL REUQIREMENTS

6.1 Use of human subjects

(a) The following definitions are used:

(1) At risk means that the human subject may be exposed to the possibility of harm - physical, biological, psychological, sociological, or other - as a consequence of an act or omission that goes beyond the application of those established and accepted methods or procedures which are in his best interests, or that increases ordinary risks of daily life, including the recognized risks inherent in his chosen occupation or field of service.

(2) Human subject means any human being who, knowingly or unknowingly, is subjected to an act or omission, whether at risk or not, the object of which is to contribute to knowledge to be gained as a part of work to be performed under the scope of this contract.

(b) The contractor, before undertaking to perform any study involving human subjects, whether at risk or not, shall insure that the following minimum conditions are complied with:

(1) The proposed study has been reviewed and approved by a committee meeting the requirements set forth in Chapter 46 of Title 45 of the Code of Federal Regulations.

(2) The number of human subjects used will be kept to the minumum number that will reasonably achieve the required results.

(3) The study must be such as to contribute significantly to scientific knowledge and have reasonable prospects of yielding important results essential to an Army research program.

(4) The study will be conducted only by persons possessing the requisite scientific qualifications. The highest degree of skill and care will be required during all stages of study of persons who conduct or assist in the study.

(5) The human subject will be informed that at any time during the course of his participation he has the right to revoke his consent and withdraw from participation without prejudice to himself.

(6) Participation by subjects will be immediately terminated if it subsequently appears that the risk to the subjects is significantly greater than anticipated at the time review and approval was granted.

Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110001-4
WARNING NOTICE: SENSITIVE INTELLIGENCE SOURCES AND METHODS INVOLVED

NOT RELEASABLE TO FOREIGN NATIONALS

Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110001-4

(7) There shall be no greater intrusion into the privacy of the human subject than is absolutely necessary for the conduct of the study involved. Except for the submission of reports and other data required by this contract, any information obtained about human subjects as a result of participation shall be held as confidential as the law allows.

(8) The study will be conducted so as to avoid all unnecessary physical or mental suffering or injury.

(9) No study will be conducted if there is any inherent reason to believe that death or disabling injury is likely to occur. Sufficient animal or laboratory experiments, or other evaluations, must have been completed to give assurance of acceptable risks prior to the use of human subjects.

(10) The degree of risk to be taken will never exceed that which is justified by the benefit to the subject and/or the humanitarian importance of the knowledge to be gained.

(11) A physician will be responsible for the medical care of subjects. Even if not the project leader, the physician will have authority to terminate the study at any time that he believes death, injury or harm is likely to result.

(12) Proper preparations will be made, and adequate facilities provided to protect the subject against all foreseeable possibilities if injury, disability or death. This includes but is not limited to hospitalization and medical treatment as may be required. In addition, all apparatus and instruments necessary to deal with likely emergency situations will be available.

(13) Human subjects will have no physical or mental conditions which will make participation more hazardous for them than it would be for normal healthy persons, unless such condition is a necessary prerequisite for the particular study involved. In any such case, the use of human subjects with such pre-existing conditions must have been specifically described and justified in the scope of the work to be performed under this contract.

(14) The scientifically qualified person conducting the study, and each member of his research team, will be prepared to terminate the subject's participation at any stage if he has reason to believe, in the exercise of the good faith, superior skill, and careful judgement required of him, that continuation is likely to result in injury, disability, or death to the human subject.

(c) The contractor, before permitting any person to participate as a human subject, whether at risk or not, shall insure that the following minimum conditions are complied with:

(1) Legally effective informed consent will be obtained by adequate and appropriate methods in accordance with the provisions of this clause.

WARNING NOTICE - SENSITIVE INTELLIGENCE SOURCES AND METHODS INVOLVED
NOT RELEASABLE TO FOREIGN NATIONALS
Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110001-4

(2) All consent must be voluntary. It must be the knowing consent of the individual or his legally authorized representative, so situated as to be able to exercise free power of choice without there having been any use of force, fraud, deceit, duress, constraint, coercion, or lawful or improper inducement. The elements of information necessary to such consent include:

(i) A fair explanation of the procedures to be followed, and their purposes, including identification of any procedures which are experimental.

(ii) A description of any attendant discomforts or risks reasonably to be anticipated.

(iii) A description of any benefits reasonably to be anticipated.

(iv) A disclosure of any appropriate alternative procedures that might be advantagious to the subject.

(v) An offer to answer any questions concerning the procedure.

(vi) An instruction that the subject is free to revoke his consent and to discontinue participation at any time without prejudice to himself.

(d) Exculpatory language through which the subject is made to waive, or appear to waive, any of his legal rights, including any release from liability for negligence, is prohibited.

(e) Prior consent by a subject or his legally authorized representative shall be obtained in all cases. Such consent shall be in writing whenever it is reasonably possible to do so. The consent form may be read to the subject or his legally authorized representative, but in any event he or his legally authorized representative must be given adequate opportunity to read it and to ask questions they might have. This consent form should then be signed by the subject or his legally authorized representative and by a witness not directly involved in the study. Oral consent may be used only when it has been specifically described and justified in the scope of the work to be performed under this contract or approved in writing by the contracting officer. When so authorized and used, oral consent is subject to all the same standards as apply to written consent, except that the signature of the subject or his legally authorized representative is not required.

(f) Prior to conduct of the study, the contractor shall submit for approval to the contracting officer's representative a detailed description of the means by which informed consent will be obtained, to include any forms to be used. Upon completion of the study, the contractor will submit to the contracting officer's representative a detailed report demonstrating compliance with paragraph (c), to include copies of the written consent if such was obtained.

(g) The contractor shall not undertake to conduct either the clinical pharmacology or clinical trails of an investigational drug unless this contract contains the clause entitled "Clinical Study of Investigational Drugs."

(h) Pursuant to [illegible]

Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110001-4

6.2 DoD Direcive 5240.1-R governing experimentation on human subjects will be followed by the contractor. Informed consent of all subjects will be obtained in writing in accordance with the guidelines issued by the Department of Health, Education and Welfare. All persons participating as human subjects, as defined in paragraph 6.1 above shall be known to possess the abilities and qualities which will be observed and analyzed during the conduct of this contract.

WARNING NOTICE: SENSITIVE INTELLIGENCE SOURCES AND METHODS INVOLVED
Approved For Release 2001/04/02 : CIA-RDP96-00788R001500110001-4

NOT RELEASABLE TO FOREIGN NATIONALS

Approved For Release 2001/04/[illegible] SECRET [illegible]96-00788R001500110001-4

JUSTIFICATION FOR SOLE SOURCE PROCUREMENT

1. (S) SRI International is uniquely qualified for this sole source procurement by virtue of a combination of experience and performance.

2. (S/NOFORN) SRI International is a recognized leader in the field of psychoenergetics and has performed similar work for other U.S. Government agencies over the past few years. Previous work, under DIA contracts MDA-908-81-C-0292 and MDA-908-92-C-0034 has formed a highly meaningful data base which will greatly enhance the value and effectiveness of this new contractural effort.

3. (S) The effort involved for a new contractor to research the same level of capability and expertise that SRI currently possesses for this area would be too time consuming and uneconomical to acquire and develop. To acquaint a new contractor in this area of expertise, if he could be found, would require several years simply to achieve the present level of expertise and competence possessed by SRI International.

WARNING NOTICE: SENSITIVE INTELLIGENCE SOURCES AND METHODS INVOLVED

Approved For Release 2001/[illegible] SECRET [illegible]96-00788R001500110001-4 NOT RELEASABLE TO FOREIGN NATIONALS